Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Search content at Prinses Máxima Centrum
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
How to position pasireotide LAR treatment in acromegaly
Eva C. Coopmans
, Ammar Muhammad
, Aart J. Van Der Lely
, Joseph A.M.J.L. Janssen
,
Sebastian J.C.M.M. Neggers
Research output
:
Contribution to journal
›
Review article
›
peer-review
50
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'How to position pasireotide LAR treatment in acromegaly'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Pasireotide
100%
Long-term Release
100%
Release Treatment
100%
Pegvisomant
46%
Consensus Criteria
30%
Tumor Growth
23%
Monotherapy
23%
Somatostatin Receptor Ligands
23%
Combination Therapy
15%
Hyperglycemia
15%
Co-receptor
7%
Young Patients
7%
Medical Treatment
7%
Headache
7%
Patient with Tumor
7%
Intolerant
7%
Second-line Therapy
7%
Somatostatin
7%
International Journals
7%
Third-line Treatment
7%
Liberal
7%
Without Diabetes
7%
Clinical Papers
7%
Blood Glucose Monitoring
7%
Combination Studies
7%
Evidence Acquisition
7%
Medicine and Dentistry
Acromegaly
100%
Pasireotide
100%
Pegvisomant
46%
Tumor Progression
23%
Monotherapy
23%
Somatostatin Receptor
23%
Combination Therapy
15%
Hyperglycemia
15%
Headache
7%
Diabetes
7%
Somatostatin
7%
Blood Glucose Monitoring
7%
Side Effect
7%
Pharmacology, Toxicology and Pharmaceutical Science
Acromegaly
100%
Pasireotide
100%
Pegvisomant
46%
Tumor Growth
23%
Monotherapy
23%
Somatostatin Receptor
23%
Combination Therapy
15%
Hyperglycemia
15%
Headache
7%
Somatostatin
7%
Side Effect
7%
Glucose
7%